why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 100 of 139 result(s) (Page 10 of 14)
Drug Name: Augtyro

Active Ingredient: repotrectinib

Approval Date: 2023-11-15

Description: To treat ROS1-positive non-small cell lung cancer

Drug Name: Defencath

Active Ingredient: taurolidine, heparin

Approval Date: 2023-11-15

Description: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter

Drug Name: Fruzaqla

Active Ingredient: fruquintinib

Approval Date: 2023-11-08

Description: To treat refractory, metastatic colorectal cancer

Drug Name: Loqtorzi

Active Ingredient: toripalimab-tpzi

Approval Date: 2023-10-27

Description: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies

Drug Name: Omvoh

Active Ingredient: mirikizumab-mrkz

Approval Date: 2023-10-26

Description: To treat ulcerative colitis

Drug Name: Agamree

Active Ingredient: vamorolone

Approval Date: 2023-10-26

Description: To treat Duchenne muscular dystrophy
Drug Trials Snapshot

Drug Name: Bimzelx

Active Ingredient: bimekizumab

Approval Date: 2023-10-17

Description: To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Drug Trials Snapshot

Drug Name: Zilbrysq

Active Ingredient: zilucoplan

Approval Date: 2023-10-17

Description: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

Drug Name: Velsipity

Active Ingredient: etrasimod

Approval Date: 2023-10-12

Description: To treat moderately to severely active ulcerative colitis in adults

Drug Name: Rivfloza

Active Ingredient: nedosiran

Approval Date: 2023-09-29

Description: To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

300×250 Ad Slot